Share-based Payment Arrangement, Expense of G1 Therapeutics, Inc. from 30 Jun 2016 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
G1 Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2016 to 30 Jun 2024.
  • G1 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2024 was $2,090,000, a 45% decline year-over-year.
  • G1 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2024 was $11,500,000, a 32% decline year-over-year.
  • G1 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $14,510,000, a 30% decline from 2022.
  • G1 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $20,589,000, a 7.8% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

G1 Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $11,500,000 $2,090,000 -$1,720,000 -45% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $13,220,000 $2,546,000 -$1,290,000 -34% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2024 2024 Q1
Q4 2023 $14,510,000 $3,209,000 -$1,191,000 -27% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q3 2023 $15,701,000 $3,655,000 -$1,130,000 -24% 01 Jul 2023 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 $16,831,000 $3,810,000 -$1,829,000 -32% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $18,660,000 $3,836,000 -$1,929,000 -33% 01 Jan 2023 31 Mar 2023 10-Q 01 May 2024 2024 Q1
Q4 2022 $20,589,000 $4,400,000 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $4,785,000 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $5,639,000 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $5,765,000 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q2 2017 $769,000 +$451,000 +142% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2017 2017 Q2
Q2 2016 $318,000 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2

G1 Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $14,510,000 -$6,079,000 -30% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 $20,589,000 -$1,730,000 -7.8% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $22,319,000 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.